Psoriasis is classified as an immune-mediated inflammatory disease, and most researchers now consider it to have autoimmune characteristics. The distinction matters less than it used to: the immune system is clearly the driving force behind psoriasis, attacking healthy skin cells and triggering inflammation throughout the body. It affects roughly 2 to 3% of the global population, with higher rates in Western Europe and other high-income regions.
Why the Label Is Complicated
Classic autoimmune diseases have a clear-cut pattern: the immune system produces antibodies that target a specific tissue in the body. In type 1 diabetes, it attacks insulin-producing cells. In rheumatoid arthritis, it attacks joint lining. For decades, psoriasis didn’t fit neatly into this box because researchers couldn’t identify a specific self-protein (called an autoantigen) that the immune system was reacting to.
That changed in 2014, when a team discovered that about two-thirds of patients with moderate-to-severe plaque psoriasis carry immune cells specifically trained to attack LL37, an antimicrobial peptide that the body naturally produces in the skin. These LL37-targeting immune cells produce inflammatory signals, can infiltrate affected skin, and their presence in the bloodstream correlates with how active the disease is. This discovery provided the strongest evidence yet that psoriasis involves a true autoimmune reaction, not just general immune dysfunction.
The medical community now broadly describes psoriasis as an “immune-mediated inflammatory disease” rather than a pure autoimmune disease. This reflects the reality that psoriasis involves both the innate immune system (the body’s rapid, nonspecific defense) and the adaptive immune system (the targeted, antibody-driven response), with complex crosstalk between the two. It’s not a case of “autoimmune or not.” It’s a disease where the immune system is the central problem, with autoimmune features layered on top of broader inflammatory dysfunction.
What Happens Inside the Skin
In healthy skin, cells in the outermost layer take about 45 days to mature, rise to the surface, and shed. In psoriatic skin, that cycle compresses to 7 to 10 days. The skin cells pile up faster than the body can shed them, creating the thick, scaly plaques that characterize the disease.
This isn’t a problem with the skin cells themselves. Since the 1980s, researchers have understood that psoriasis originates in the immune system, particularly in T cells. Here’s the cascade: immune cells in the skin become activated and release signaling molecules called cytokines. Two of these, IL-23 and IL-17, form a self-amplifying loop. IL-23 drives the expansion of a specific type of T cell that pumps out IL-17. IL-17, in turn, acts on skin cells to trigger the production of even more inflammatory proteins, which recruit more immune cells. The result is a feed-forward cycle where inflammation keeps fueling itself.
IL-17 is considered the major effector cytokine in psoriasis. Working alone or alongside another inflammatory signal called TNF-alpha, it causes skin cells to release a cascade of proteins associated with psoriatic plaques. Another cytokine, IL-22, contributes to the thickened, scaly appearance of affected skin by driving excess growth in the outer skin layer. Even innate immune cells in the skin that aren’t part of the adaptive (targeted) immune response produce IL-17 and IL-22, which is one reason the disease doesn’t fit a simple autoimmune framework.
Genetics and Triggers
Psoriasis has a strong genetic component. One of the most well-established genetic links is a variant called HLA-C*06:02, which is part of the immune system’s machinery for recognizing foreign proteins. Carrying this variant significantly increases the risk of developing psoriasis and can even influence how well certain treatments work. Multiple other genes involved in immune regulation also contribute, which is why the disease runs in families but doesn’t follow a simple inheritance pattern.
Genetics load the gun, but environmental triggers pull it. Psoriasis flares can be set off by physical skin injury (cuts, sunburns, tattoos, even prolonged pressure), infections, stress, and certain medications. The tendency for new psoriatic plaques to appear at sites of skin injury is called the Koebner phenomenon. A cut on your arm, a scrape on your knee, even an acupuncture needle can trigger a new lesion in previously healthy skin. This happens because the trauma activates the local immune response, which in someone genetically predisposed, kicks off the inflammatory cascade described above.
Psoriasis as a Systemic Disease
One of the most important shifts in understanding psoriasis is recognizing that it’s not limited to the skin. The visible plaques are the most obvious part of a body-wide inflammatory state. This systemic inflammation explains why psoriasis is linked to higher rates of cardiovascular disease, metabolic syndrome, and depression.
The most direct extension beyond the skin is psoriatic arthritis. Up to 30% of people with psoriasis eventually develop inflammatory joint disease. In a population-based study, about 60% of patients had skin symptoms first, with a median gap of roughly 10 years between their psoriasis diagnosis and the onset of joint inflammation. The remaining 40% developed skin and joint symptoms around the same time. Joint stiffness, swelling, and pain, particularly in the fingers, toes, and lower back, are early signs worth paying attention to if you have psoriasis.
How Diagnosis Works
Psoriasis is usually diagnosed by appearance alone. The hallmark is sharply bordered, red, scaly plaques most commonly found on the elbows, knees, scalp, and lower back. Scraping away the silvery scale often reveals tiny points of bleeding underneath, called the Auspitz sign. There’s no blood test for psoriasis.
When the diagnosis is uncertain, a small skin biopsy can confirm it. Under a microscope, psoriatic skin shows a distinctive pattern: thickened outer layers, abnormally dilated blood vessels, and clusters of immune cells. Tiny collections of white blood cells called Munro’s microabscesses appear in about 75% of cases and are a strong diagnostic marker. Doctors may also test for fungal infections or drug reactions, which can sometimes look similar.
How Treatments Target the Immune System
Because psoriasis is driven by the immune system, the most effective modern treatments work by dialing down specific parts of the immune response. Mild disease is often managed with topical treatments and light therapy, but moderate-to-severe psoriasis increasingly calls for biologic medications that target the inflammatory pathway at precise points.
The first generation of biologics blocked TNF-alpha, one of the key inflammatory signals in psoriatic skin. These drugs reduce inflammation broadly and are also effective for psoriatic arthritis. A second wave targets IL-12 and IL-23 by binding to a protein subunit these two cytokines share, which interrupts the signaling that drives T cell activation. Newer biologics go further, targeting IL-17 or IL-23 individually. Because IL-17 is the primary driver of the inflammatory loop in psoriatic skin, drugs that block it can produce dramatic clearing of plaques.
The success of these targeted therapies is itself strong evidence that psoriasis is an immune-driven disease. Each new biologic essentially tests a hypothesis about which immune signal matters most, and the results have confirmed that the IL-23/IL-17 pathway sits at the center of the disease. For people living with psoriasis, this means treatments are more effective and more targeted than they were even a decade ago, with options that address the root immune dysfunction rather than just managing symptoms on the skin’s surface.